2014-03-21 21:22:47 UTC

Gastroenterology Podcast March 2014: Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Chronic Hepatitis C

A phase-3 study in the March issue of Gastroenterology examined the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Dr. Kuemmerle discusses the results with first author Dr. Maria Buti; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Buti M, Agarwal K, Horsmans Y, et al. Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology 2014; March; 146(3): 744-753
Abstract

 

 

Duration: 14.52m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Hepatitis C

Digestive Disease Week® (DDW)

May 6, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Earn CME and MOC Credit in the March Journals

March 27, 2017

Three new quizzes are now available covering celiac disease, hepatitis C and defecatory disorders.

New HCV Treatments Work Well for Severe Liver Disease

March 21, 2017

New therapies are safe and effective in patients with decompensated cirrhosis. Find out more in the AGA-MedPage Today Reading Room.